SPY343.38+1.37 0.40%
DIA282.95+0.92 0.33%
IXIC11,516.49+37.51 0.33%

OPKO's BioReference Labs Highlights Launch Of COVID-19 Testing Program For New York City Schools Throughout 2020-2021 School Year

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.

· 10/09/2020 08:01

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.

BioReference Laboratories, Inc., an OPKO Health Company. (PRNewsfoto/BioReference Laboratories, Inc)

Continuing a strategic collaboration with New York City, the Department of Health, New York City Health and Hospital Corporation (NYC Health + Hospitals), the Test & Trace Corp, and the Department of Education, BioReference is performing COVID-19 molecular testing for NYC schools. In addition, BioReference is collecting specimens from principals, teachers, administration and students from over 950 schools across NYC.

"This school year for New York City and other school systems around the world is vastly different due to the global pandemic, and BioReference is privileged to aid in keeping NYC schools safe," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories.